Board of Directors
A Director of the Company since March 2018, Mr. Messina is the Founder, President and Chief Executive Officer of The Benchmark Company, LLC, an investment banking and financial advisory firm.
Mr. Messina obtained a B.A. from the University of Massachusetts Amherst.
Cristina Csimma PharmD, MHPDirector
A director of the Company since September 2010, Dr. Csimma also serves on the Board of Directors for Neuralstem, Inc. (nervous system diseases). She has been engaged in strategic advisory roles with the biopharmaceutical and venture capital industries, as well as government and patient organizations.
Dr. Csimma was The Executive Chair of the Board of Directors of Exonics Therapeutics (rare diseases), a director at Vtesse Inc. (rare diseases, acquired by Sucampo in March 2017), and was a President and the founding Chief Executive Officer of Cydan Development, Inc. (therapeutics for orphan diseases) from November 2012 until April 2014, and a director of Cydan from April 2014 until December 2014. She served as Vice President, Drug Development, of Virdante Pharmaceuticals, Inc., from January 2009 to May 2011, prior to which she was a principal of Clarus Ventures, LLC (life sciences venture capital), from 2006 through 2008.
During her tenure at Wyeth Research (pharmaceuticals), Dr. Csimma was Senior Director/Director, Experimental Medicine and Translational Research from 2001 to 2006, and Director, Clinical Research and Development from 2000 to 2001. Prior to Wyeth, Dr. Csimma held various positions, including Associate Director, Clinical Research, with Genetics Institute from 1988 to 2000, and was a Clinical Pharmacist with Dana-Farber Cancer Institute from 1983 to 1988.
Dr. Csimma holds B.S. and Doctor of Pharmacy degrees from the Massachusetts College of Pharmacy and Allied Health Sciences, and a Master of Health Professions from Northeastern University.
James A. GeraghtyChairman of the Board
Jim Geraghty has been a director of the Company since May 2015 and was elected Chairman of the Board in July 2015. He is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty serves as Chairman of the Board of Idera Pharmaceuticals. He also serves a director on the Boards of Pieris Pharmaceuticals, Inc., Fulcrum Therapeutics, Inc., Voyager Therapeutics, Inc., and BIO Ventures for Global Health.
Earlier, Mr. Geraghty served as an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund. He served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent 20 prior years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases (HAND) program, under which the company supported innovative development programs on a non-commercial basis.
He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, Mr. Geraghty holds a M.S. from the University of Pennsylvania and a B.A. from Georgetown University.Chairman of the Board
Mary Ann Gray Ph.D.Director
Dr. Mary Ann Gray was appointed to Juniper’s board of directors in March 2016 and serves as audit committee Chair.
Dr. Gray has more than 20 years of experience in the biotechnology and biopharmaceutical industry. She is currently President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
Previously, a Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund, Dr. Gray also covered large- and small-cap biotechnology companies while an equity research analyst at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray began her career as a scientist focused on new drug development at Schering-Plough and NeoRx Corporation.
Dr. Gray holds a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
In addition to Juniper, Dr. Gray also serves on the board of directors of two other public biotechnology companies. She is a director of Galena Biopharma, Inc. (oncology) and Senomyx Inc. (technology). Additionally, Dr. Gray was lead director of Dyax Corp. (pharmaceuticals) until its acquisition by Shire plc in early 2016. two other public biotechnology companies. She served on the boards of Acadia Pharmaceuticals (CNS treatments) and TetraLogic Pharmaceuticals Corporation (oncology and infectious disease therapeutics). At Acadia she served as chair of the audit committee and also served on the compensation committee. Dr. Gray previously served as lead director of Dyax Corp. until its acquisition by Shire plc (specialty biopharmaceuticals) in January 2016. Earlier in her career, Dr. Gray managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute and worked in the hospital laboratory.Financial Expert
Ms. Good, a director of the Company since September 2017, is the co-founder, President, and Chief Executive Officer at Trevi Therapeutics, a late-stage clinical development company. Prior to founding Trevi, she served as President and Chief Executive Officer and as Chief Financial Officer at Penwest Pharmaceuticals, where she successfully led the transition of Penwest Pharmaceuticals from a development stage company to a profitable commercial stage company generating annual revenues in excess of $50 million and negotiating the sale of the Company to its major partner.
Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good is a board member of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia.
Ms. Merrifield, a director of the Company since July 2015, was formerly the President and Chief Executive Officer of PathoGenetix, Inc., a genomics company. Prior to that, she spent 18 years at the Genzyme Corporation where, among other roles, she served as Senior Vice President, Business Excellence, President of Genzyme Biosurgery, and President of Genzyme Genetics. She was previously a partner at Bain and Company and an investment officer at Aetna Life & Casualty.
Ms. Merrifield earned a Bachelor of Arts in Zoology and a Master of Education from the University of Maine, and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College. She is also a Director of Flexion Therapeutics and InVivo Therapeutics, and a Trustee of two MassMutual investment funds.
Alicia Secor, MBAPresident and Chief Executive Officer
Alicia Secor joined Juniper Pharmaceuticals as Chief Executive Officer in August 2016 and serves as a Director of the Company. Ms. Secor brings more than 25 years of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.
Ms. Secor joined Juniper from Zafgen, Inc., where she was Chief Commercial Officer and played a key role in advancing the company to a Phase 3 pre-commercialization status. Previously, Ms. Secor served as Senior Vice President and Chief Operating Officer at Synagev BioPhamra Corp, and spent 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business. During her tenure at Genzyme, Ms. Secor led fully integrated businesses, successfully launching products and achieving sustained revenue growth. Ms. Secor spearheaded several strategic transactions and built high performance teams, resulting in consistent growth and profitability across multiple Genzyme businesses including biomaterials, surgical devices, and injectable therapeutics. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, and at Centocor, Inc. (a Johnson & Johnson Company) in clinical and commercial operations. She began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also currently serves as a member of the Board of Directors for the Foundation for Prader-Willi Research.
Ms. Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire.
Nikin Patel PhD, MRPharmSChief Operating Officer
Dr. Nikin Patel co-founded and is the former Chief Executive Officer of Molecular Profiles (now known as Juniper Pharma Services). He joined our board of directors in September 2013 when Molecular Profiles was acquired by Juniper Pharmaceuticals (formerly Columbia Laboratories). Dr. Patel has over 20 years of management and technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry accolade, the Queen’s Award for Enterprise, won by Molecular Profiles in both 2007 and 2011 in the Innovation category.
Dr. Patel holds a first class honours degree and PhD in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS). Dr. Patel is also a co-founder of Locate Therapeutics, a specialist regenerative medicine and device company and was a director from 2001 through 2014.
Martyn Davies BSc, PhD, FRPharmS, CChem, FRSCAdvisor to the Board
Dr. Martyn Davies has over 30 years’ experience in the pharmaceutical, biopharmaceutical and drug delivery fields. He serves as an Advisor to its Board of Directors.
Dr. Davies is a Professor and former Head of School at the University of Nottingham School of Pharmacy, and cofounded the Laboratory of Biophysics and Surface Analysis (LBSA), the leading Research Division of the School. The LBSA has an international reputation and track record for the development and study of drug delivery and biomaterials and was the first grouping to receive the GlaxoSmithKline International Achievement Award (2003), given for "internationally recognized work on drug delivery and new techniques for surface and interface analysis".
In 1997, Dr. Davies co-founded Juniper Pharma Services (f/k/a Molecular Profiles Ltd.), a successful spin-out from the LBSA, and served as its Founder-Chairman until its acquisition by Juniper Pharmaceuticals (f/k/a Columbia Laboratories) in September 2013, at which time he was appointed Advisor to the company’s Board of Directors. He played a key role in Molecular Profiles’ strategic development and also in leading and consulting on many technical projects for clients.
Dr. Davies holds a first class honours degree in Pharmacy from Brighton Polytechnic and a Ph.D. from King's College, University of London. He has authored or co-authored more than 380 published scientific articles, has trained more than 100 postgraduate and research scientists, is a Fellow of the Royal Society for Chemistry (FRSC) and Royal Pharmaceutical Society of Great Britain (FRPharmS), the American Institute of Biological Engineering, the UK Association of Pharmaceutical Scientists, and the Controlled Release Society, and is a past President of the Controlled Release Society (2011-12). He also serves on the editorial boards of six science journals.